Vish Seshadri, Abeona Therapeutics CEO

FDA wants more da­ta from Abeona Ther­a­peu­tics as it push­es for BLA

Abeona Ther­a­peu­tics pushed back plans to sub­mit its gene ther­a­py for a rare skin con­di­tion af­ter the FDA asked the com­pa­ny for more da­ta about …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.